EMA Clarifies Clinical Requirements in Adult, Pediatric Heart Failure Trials

Drug Industry Daily
A A
The European Medicines Agency Wednesday released final guidance on the primary and secondary endpoints sponsors should use to evaluate drugs to treat acute heart failure — along with recommendations on designing and conducting such studies in children.

To View This Article:

Login

Subscribe To Drug Industry Daily